Insider Transactions in Q1 2024 at Regeneron Pharmaceuticals, Inc. (REGN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+3.31%
|
$302,400
$378.98 P/Share
|
|
Jan 04
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-1.49%
|
$313,614
$917.05 P/Share
|
|
Jan 04
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.13%
|
$189,000
$378.98 P/Share
|
|
Jan 03
2024
|
Joseph J Larosa EVP General Counsel and Secret |
SELL
Payment of exercise price or tax liability
|
Direct |
24,493
-38.25%
|
$22,337,616
$912.3 P/Share
|
|
Jan 03
2024
|
Joseph J Larosa EVP General Counsel and Secret |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+34.68%
|
$13,566,000
$399.66 P/Share
|
|
Jan 03
2024
|
Christopher R. Fenimore VP Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
7,512
-18.97%
|
$6,850,944
$912.3 P/Share
|
|
Jan 03
2024
|
Christopher R. Fenimore VP Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.13%
|
$4,770,000
$477.66 P/Share
|
|
Jan 03
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
688
-2.97%
|
$627,456
$912.3 P/Share
|
|
Jan 03
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,100
+4.54%
|
$415,800
$378.98 P/Share
|
|
Jan 03
2024
|
Bonnie L Bassler Director |
SELL
Open market or private sale
|
Direct |
826
-37.41%
|
$754,964
$914.0 P/Share
|
|
Jan 03
2024
|
Bonnie L Bassler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
826
+27.22%
|
$313,880
$380.95 P/Share
|
|
Jan 02
2024
|
George Yancopoulos President and Chief Scientific |
SELL
Open market or private sale
|
Indirect |
33,696
-8.56%
|
$30,326,400
$900.0 P/Share
|
|
Jan 02
2024
|
Craig B. Thompson Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+22.92%
|
-
|
|
Jan 02
2024
|
Kathryn Guarini Director |
BUY
Grant, award, or other acquisition
|
Direct |
42
+12.96%
|
-
|
|
Jan 02
2024
|
David P Schenkein Director |
BUY
Grant, award, or other acquisition
|
Direct |
42
+12.96%
|
-
|
|
Jan 02
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
274
-1.79%
|
$239,202
$873.91 P/Share
|
|
Jan 02
2024
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
421
-1.87%
|
$373,848
$888.34 P/Share
|
|
Jan 02
2024
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
650
+2.81%
|
$245,700
$378.98 P/Share
|
|
Jan 02
2024
|
Christine A Poon Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+5.85%
|
-
|
|
Jan 02
2024
|
Huda Y Zoghbi Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.9%
|
-
|
|
Jan 02
2024
|
Huda Y Zoghbi Director |
SELL
Open market or private sale
|
Direct |
1,117
-47.25%
|
$1,005,300
$900.0 P/Share
|
|
Jan 02
2024
|
Huda Y Zoghbi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,117
+32.09%
|
$436,747
$391.92 P/Share
|
|
Jan 02
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.9%
|
-
|
|
Jan 02
2024
|
N Anthony Coles Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.84%
|
-
|
|
Jan 02
2024
|
Michael S Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+8.9%
|
-
|
|
Jan 02
2024
|
Joseph L Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+2.07%
|
-
|
|
Jan 02
2024
|
George L Sing Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+0.51%
|
-
|
|
Jan 02
2024
|
Arthur F Ryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
135
+0.73%
|
-
|
|
Jan 02
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.04%
|
$89,500
$895.69 P/Share
|